European Commission grants Bristol Myers Squibb approval for Opdivo to treat RCC
Bristol Myers Squibb has been granted approval by the European Commission (EC) for the use of Opdivo (nivolumab) in combination with Cabometyx (cabozantinib) to treat adults with advanced